BSI-201 Chemical Structure
ABT-888 (Veliparib) is a potent poly (ADP-ribose) polymerase (PARP) inhibitor of PARP-1 and PARP-2 with Ki of 5.2 nM and 2.9 nM, respectively.
Olaparib(AZD2281, KU0059436) is a selective inhibitor of PARP-1 and PARP-2 enzymes with IC50 of 5 nM and 1 nM, respectively.
AG-014699 (Rucaparib, PF-01367338) is an inhibitor of PARP with a Ki of 1.4 nM.
INO-1001 is a novel potent PARP inhibitor with an IC50 of 3 nM.
AG14361 is a potent inhibitor of purified full-length human PARP-1 with Ki of less than 5 nM.
MK-4827 is a potent, selective PARP 1/2 inhibitor with IC50 of 3.8 and 2.1 nM for PARP1 and 2, respectively.
Pemetrexed (Alimta) is a thymidylate synthase, DHFR and glycinamide ribonucleotide formyltransferase inhibitor with an IC50 of 25, 34, 220 nM.
A glycopeptide antibiotic produced by the bacterium Streptomyces verticillus.
Clofarabine inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase
BSI-201 is a potent PARP1 inhibitor with strong anti-neoplastic effect. BSI-201 covalently binds and inhibits PARP-1. When given as a single agent and in combination with other cytotoxic agents, BSI-201 is active against a broad range of cancer cells in culture. BSI-201 has first-in-class and best-in-class potential as targeted therapy for several types of cancer. BSI-201 has demonstrated activity in multiple types of solid tumors, with prolonged inhibition of its target. BSI-201 has shown a strong safety profile. BSI-201 is a leading candidate in the field of PARP inhibitors and is the furthest along in clinical development of this novel therapeutic approach. [1][2][3]
| Molecular Weight (WM): | 292.03 |
|---|---|
| Formula: | C7H5IN2O3 |
| CAS No.: | 160003-66-7 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥58mg/mL |
| Water <1mg/mL | |
| Ethanol ≥37mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
A collection of 864 bioactive compounds
A collection of 481 inhibitors
A collection of 194 kinase inhibitors
A collection of 85 tyrosine kinase inhibitors.
A collection of 426 FDA approved drugs
A collection of 139 natural products
A collection of 40 chemotherapeutic agents
A unique collection of 17 small molecule modulators
A unique collection of 47 small molecule inhibitors
A unique collection of 63 GPCR small molecules

Representative Western blot analysis and quantification of the mean intensity of the band of IKB phosphorylation (E) and caspase 3 activation (F) in Wt neurons incubated with TWEAK either alone or in combination with the PARP-1 inhibitor BSI-201.
|
Representative Western blot analysis and quantification of the mean intensity of the band of IKB phosphorylation (E) and caspase 3 activation (F) in Wt neurons incubated with TWEAK either alone or in combination with the PARP-1 inhibitor BSI-201.
Data from [Neuroscience 2010.October;171:1256–1264] BSI-201 purchased from Selleck

Asst Prof. Joseph A. De SotoLaboratory of Translational Oncology Department of Health, Injury, and Disease Management Uniformed Services University of the Health Sciences
Keywords:buy BSI-201 | BSI-201 supplier | purchase BSI-201 | BSI-201 cost | BSI-201 manufacturer | order BSI-201 | BSI-201 distributor